@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix chebi: . @prefix species: . @prefix occursIn: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: species:9606; rdf:object chebi:23965; rdf:predicate belv:decreases; rdf:subject schem:Goserelin; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:Goserelin) -| a(CHEBI:estradiol)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_4; pav:version "1.4" . sub:_2 dce:identifier "http://www.netdoctor.co.uk/medicines/100004320.html"; dce:title "http://www.netdoctor.co.uk/medicines/100004320.html"; dce:type "Other" . sub:_3 prov:value "The growth of some breast cancers is stimulated by oestrogen, and that of some prostate cancers by testosterone. Because these cancers are sensitive to the sex hormones, goserelin can be used in their treatment. Reducing the body's levels of these hormones causes the tumours to shrink."; prov:wasQuotedFrom sub:_2 . sub:_4 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource sub:_2; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:43.966+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }